GILEAD SCIENCES, INC.
NASDAQ: GILD
▲
76.94
+0.61
+0.80%
1 Day
-
Open
76.62
-
Previous Close
76.33
-
Volume (Avg)
8.07M (5.38M)
-
Day's Range
76.27-77.02
-
52Wk Range
57.17-89.74
-
Market Cap.
95.97B
-
Dividend Rate (Yield)
3.00 (3.93%)
-
Beta
0.40
-
Shares Outstanding
1.25B
-
P/E Ratio (EPS)
17.25 (4.42)
Top Stories
-
3 Relatively Safe Stocks to Buy if a Recession Is on the Way
The Motley Fool 5/20/2023 -
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Benzinga -
Cramer's Lightning Round: Stay away from Gilead Sciences
CNBC -
Clinics are losing funding for HIV prevention drugs and screenings. Here's what that means
Austin American-Statesman -
Why CymaBay Therapeutics Stock Nose-Dived This Week
The Motley Fool 5/19/2023 -
Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use
Zacks.com -
Thousands march at AIDS Walk New York 2023 in Central Park
CBS New York -
Mary J. Blige’s Purpose Ball Was The Embodiment Of Community
Vibe -
Ananda Lewis And Free Marie’s Full Circle Moment
Vibe -
Pfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults
Zacks.com -
Gilead Sciences Strikes New Deal with Arcus Biosciences
TipRanks -
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Benzinga -
Abortion pill case heads back to federal appeals court: What’s at stake
MarketWatch -
GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100?
InvestorPlace -
3 Analyst Upgrades That Smart Investors Won’t Ignore
Investorplace News 5/17/2023 -
4 big analyst picks: Meta stock a buy on sprightly revenue prospects
Investing.com -
Black trans women celebrated at 'Strength of a Woman' festival
WXIA-TV Atlanta -
Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases
Zacks.com
